.Pharmacolibrary.Drugs.ATC.A.A10BD15 .Pharmacolibrary.Drugs.ATC.A.A10BD15| name: | MetforminAndDapagliflozin |
| ATC code: | A10BD15 | route: | oral |
| n-compartments | 1 |
Fixed-dose oral combination of metformin, a biguanide antihyperglycemic agent, and dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, used for the treatment of type 2 diabetes mellitus in adults. Both components work synergistically to improve glycemic control. This combination is approved and used in clinical practice.
Population pharmacokinetics estimated for healthy adult subjects as no direct clinical population PK model for the fixed-dose combination found in published literature. Individual PK parameters for metformin and dapagliflozin were considered based on referenced studies for the separate agents. Values here are pharmacologically reasonable estimates for a 1000 mg metformin and 10 mg dapagliflozin immediate-release oral combination, single dose, in adults.
Dhillon, S (2019). Dapagliflozin: A Review in Type 2 Diabetes. Drugs 79(10) 1135–1146. DOI:10.1007/s40265-019-01148-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31236801
Scheen, AJ (2015). Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75(1) 33–59. DOI:10.1007/s40265-014-0337-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/25488697